JGC
ARCT icon

J. Goldman & Co’s Arcturus Therapeutics ARCT Stock Holding History

J. Goldman & Co’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-105,000
Closed -$1.94M – 559
2025
Q3 		$1.94M Buy
+105,000
New +$1.69M 0.05% 279
2014
Q4 		– Sell
-16,257
Closed -$1.76M – 186
2014
Q3 		$1.76M Buy
+16,257
New +$2.12M 0.11% 187

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

J. Goldman & Co's ARCT Position: Q4 2025 in Review

J. Goldman & Co sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 22,118 shares — an estimated $408K sold.

J. Goldman & Co first reported a position in ARCT in Q2 2014 and held it in 5 quarters. The position peaked at $5.02M in Q4 2024. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

  • J. Goldman & Co reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 22,118 Arcturus Therapeutics shares in Q4 2025, an estimated $408K.
  • J. Goldman & Co first reported a position in Arcturus Therapeutics in Q2 2014 and held it in 5 quarters.
  • J. Goldman & Co's Arcturus Therapeutics position peaked at $5.02M in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.